Literature DB >> 16051832

Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor.

Ann Chahroudi1, Rahul Chavan, Natalia Kozyr, Natalia Koyzr, Edmund K Waller, Guido Silvestri, Mark B Feinberg.   

Abstract

The presumed broad tropism of poxviruses has stymied attempts to identify both the cellular receptor(s) and the viral determinant(s) for binding. Detailed studies of poxvirus binding to and infection of primary human cells have not been conducted. In particular, the determinants of target cell infection and the consequences of infection for cells involved in the generation of antiviral immune responses are incompletely understood. In this report, we show that vaccinia virus (VV) exhibits a more restricted tropism for primary hematolymphoid human cells than has been previously recognized. We demonstrate that vaccinia virus preferentially infects antigen-presenting cells (dendritic cells, monocytes/macrophages, and B cells) and activated T cells, but not resting T cells. The infection of activated T cells is permissive, with active viral replication and production of infectious progeny. Susceptibility to infection is determined by restricted expression of a cellular receptor that is induced de novo upon T-cell activation and can be removed from the cell surface by either trypsin or pronase treatment. The VV receptor expressed on activated T cells displays unique characteristics that distinguish it from the receptor used to infect cell lines in culture. The observed restricted tropism of VV may have significant consequences for the understanding of natural poxvirus infection and immunity and for poxvirus-based vaccine development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051832      PMCID: PMC1182677          DOI: 10.1128/JVI.79.16.10397-10407.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

Review 1.  Diagnosis and management of smallpox.

Authors:  Joel G Breman; D A Henderson
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

3.  Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera.

Authors:  B M Ward; B Moss
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function.

Authors:  L Jenne; C Hauser; J F Arrighi; J H Saurat; A W Hügin
Journal:  Gene Ther       Date:  2000-09       Impact factor: 5.250

5.  Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation.

Authors:  Maximilian Diehn; Ash A Alizadeh; Oliver J Rando; Chih Long Liu; Kryn Stankunas; David Botstein; Gerald R Crabtree; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

6.  Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes.

Authors:  R Drillien; D Spehner; A Bohbot; D Hanau
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

7.  The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis).

Authors:  G M Zaucha; P B Jahrling; T W Geisbert; J R Swearengen; L Hensley
Journal:  Lab Invest       Date:  2001-12       Impact factor: 5.662

8.  Poxvirus infection rapidly activates tyrosine kinase signal transduction.

Authors:  J Masters; A A Hinek; S Uddin; L C Platanias; W Zeng; G McFadden; E N Fish
Journal:  J Biol Chem       Date:  2001-10-08       Impact factor: 5.157

9.  Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice.

Authors:  P Björck
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

10.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

View more
  40 in total

1.  Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication.

Authors:  Ramtin Rahbar; Thomas T Murooka; Anna A Hinek; Carole L Galligan; Antonella Sassano; Celeste Yu; Kishore Srivastava; Leonidas C Platanias; Eleanor N Fish
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

Authors:  Ningjie Hu; Richard Yu; Cecilia Shikuma; Bruce Shiramizu; Mario A Ostrwoski; Qigui Yu
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

3.  Role for CCR5 in dissemination of vaccinia virus in vivo.

Authors:  Ramtin Rahbar; Thomas T Murooka; Eleanor N Fish
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

4.  Primary human leukocyte subsets differentially express vaccinia virus receptors enriched in lipid rafts.

Authors:  Daniel Byrd; Tohti Amet; Ningjie Hu; Jie Lan; Sishun Hu; Qigui Yu
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

Review 5.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

6.  The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo.

Authors:  Lorena F D de Freitas; Rafael P Oliveira; Mariana C G Miranda; Raíssa P Rocha; Edel F Barbosa-Stancioli; Ana Maria C Faria; Flávio G da Fonseca
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

9.  Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.

Authors:  Valérie Abadie; Olivia Bonduelle; Darragh Duffy; Christophe Parizot; Bernard Verrier; Béhazine Combadière
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

10.  A differential role for macropinocytosis in mediating entry of the two forms of vaccinia virus into dendritic cells.

Authors:  Kerrie J Sandgren; John Wilkinson; Monica Miranda-Saksena; Gerald M McInerney; Karen Byth-Wilson; Phillip J Robinson; Anthony L Cunningham
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.